Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics, Inc. announced that the European Commission has granted Marketing Authorization for LYTENAVA (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD in the EU.
[Outlook Therapeutics, Inc.]
Press Release